Inclacumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| type = mab

| image =

| alt =

| mab_type = mab

| source = u

| target = selectin P

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 1256258-86-2

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = A6734I702L

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank =

| ChemSpiderID = none

| KEGG = D10356

| C = 6452 | H = 9930 | N = 1730 | O = 2024 | S = 42

| synonyms = LC1004-002

}}

Inclacumab (LC1004-002) (INN) is a human monoclonal antibody designed for the treatment of cardiovascular disease.{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 | journal = WHO Drug Information | volume = 25 | issue = 4 | year = 2011 | url =https://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf }}[http://www.ama-assn.org/resources/doc/usan/x-pub/inclacumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Inclacumab], American Medical Association.{{cite journal |vauthors=Stähli BE, Gebhard C, Duchatelle V, Cournoyer D, Petroni T, Tanguay JF, Robb S, Mann J, Guertin MC, Wright RS, L L'Allier P, Tardif JC |title=Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial |journal=J Am Heart Assoc |volume=5 |issue=11 |date=November 2016 |pmid=27852589 |pmc=5210344 |doi=10.1161/JAHA.116.004255 }}{{cite journal |vauthors=Stähli BE, Tardif JC, Carrier M, Gallo R, Emery RW, Robb S, Cournoyer D, Blondeau L, Johnson D, Mann J, Lespérance J, Guertin MC, L'Allier PL |title=Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial |journal=J. Am. Coll. Cardiol. |volume=67 |issue=3 |pages=344–6 |date=January 2016 |pmid=26796402 |doi=10.1016/j.jacc.2015.10.071 |doi-access=free }}{{cite journal |vauthors=Morrison M, Palermo G, Schmitt C |title=Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects |journal=Eur. J. Clin. Pharmacol. |volume=71 |issue=11 |pages=1365–74 |date=November 2015 |pmid=26363899 |doi=10.1007/s00228-015-1938-4 |s2cid=468125 }}{{cite journal |vauthors=Schmitt C, Abt M, Ciorciaro C, Kling D, Jamois C, Schick E, Solier C, Benghozi R, Gaudreault J |title=First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin |journal=J. Cardiovasc. Pharmacol. |volume=65 |issue=6 |pages=611–9 |date=June 2015 |pmid=25714598 |pmc=4461388 |doi=10.1097/FJC.0000000000000233 }}{{cite journal |vauthors=Schmitt C, Mudie N, Ciorciaro C, Gaudreault J |title=Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers |journal=J. Cardiovasc. Pharmacol. |volume=65 |issue=4 |pages=386–92 |date=April 2015 |pmid=25602360 |doi=10.1097/FJC.0000000000000211 |s2cid=19526048 }}{{cite journal |vauthors=Tardif JC, Tanguay JF, Wright SR, Duchatelle V, Petroni T, Grégoire JC, Ibrahim R, Heinonen TM, Robb S, Bertrand OF, Cournoyer D, Johnson D, Mann J, Guertin MC, L'Allier PL |title=Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial |journal=J. Am. Coll. Cardiol. |volume=61 |issue=20 |pages=2048–55 |date=May 2013 |pmid=23500230 |doi=10.1016/j.jacc.2013.03.003 |doi-access=free }}{{cite journal |vauthors=Kling D, Stucki C, Kronenberg S, Tuerck D, Rhéaume E, Tardif JC, Gaudreault J, Schmitt C |title=Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies |journal=Thromb. Res. |volume=131 |issue=5 |pages=401–10 |date=May 2013 |pmid=23522853 |doi=10.1016/j.thromres.2013.02.020 }}

The antibody is outlicensed by Roche.{{cite web |title=Form 8K - Entry into a Material Definitive Agreement Between Global Blood Therapeutics, Inc. and Hoffmann-La Roche Inc. |url=https://www.sec.gov/Archives/edgar/data/1629137/000117184318006225/f8k_082218.htm |publisher=United States Securities and Exchange Commission}}